ALX Oncology Holdings Inc (NAS:ALXO)
$ 8.43 -0.09 (-1.06%) Market Cap: 439.20 Mil Enterprise Value: 297.20 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 34/100
Back to the Transcripts List

ALX Oncology Holdings Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 08:00PM GMT
Release Date Price: $53.9 (-1.12%)
Jaume Pons
ALX Oncology Holdings Inc. - President, CEO & Director

Good morning. My name is Jaume Pons. I am the CEO of ALX Oncology. After the usual disclaimers in Slide #1 and some picture of us in our background in Slide #2, let's move to Slide #3.

ALX Oncology is a clinical-stage immuno-oncology company that is focused in the CD47 pathway. ALX148, our Phase II clinical candidate, is a CD47 blocker that is designed to be used in combination. This design has shown in the clinic a very good tolerability profile that has enable higher dosing. And in the clinic, this higher dosing has enabled greater efficacy.

At this moment, we have clinical proof of principle, both in hematological and solid tumors. Our initial focus is on solid tumors, MDS and AML. In addition to ALX148, we have a second compound that we call SIRPalpha TRAAC that would be an IND by the end of '22.

CD47 -- in the Slide #4, CD47 as a target is highly stress in tumor cells, here on the left, in red, but it's also highly present on normal cells, in black. Therefore, if we use CD47 as a tumor associated

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.